A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

This study consisted of:

- Induction Period (dosing at Weeks 0, 2, and 4)

- Maintenance Dosing (dosing every 4 weeks up to Week 260)

- End of Treatment Visit that occurred at Week 262/Withdrawal Visit and a Safety Follow-up
Visit (SFU; 12 weeks after final dose)

Inclusion Criteria:

- Subject participated in study C87085 [NCT00552058] in which the subject completed the
study at Week 6

- Subject is capable of providing informed consent, which must be obtained prior to any
study related procedures

- Have a chest X-ray taken at Visit 1 that is read by a qualified radiologist or
pulmonary physician, with no evidence of current active Tuberculosis (TB) or old
inactive TB

- Subject has taken a TB survey and is committed to comply with TB prophylaxis if
applicable

Exclusion Criteria:

- Subject is experiencing an ongoing serious adverse event assessed as being related to
study medication or is experiencing a serious adverse event that is still not
assessable

- Subject has an intercurrent illness that requires termination of treatment, such as a
serious infection (e.g. TB, pneumonia, sepsis, pyelonephritis, fistula abscess)

- Subject is non-compliant with TB prophylactic treatment (if applicable)

- Subject has had a chest X-ray at Visit 1 that shows an abnormality suggestive of a
malignancy or active infection, including TB

- Female who is pregnant or breast feeding

- Female of child bearing age or post puberty males not practicing effective birth
control

- Subject is expecting to receive any live virus or bacterial vaccination within 3
months of first Study Medication administration, during the trial or 3 months after
last dose of study drug